Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Victoria Profeta, Kellie McIntyre, McKenzie Wells, Courtney Park & David R Lynch. (2023) Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia. Expert Opinion on Investigational Drugs 32:1, pages 5-16.
Read now
Read now
Alexandra Mazur, Madison Fangman, Rani Ashouri, Arianna Arcenas & Sylvain Doré. (2021) Nrf2 as a therapeutic target in ischemic stroke. Expert Opinion on Therapeutic Targets 25:3, pages 163-166.
Read now
Read now
Ranjana Bhandari, Japneet Kaur, Simerpreet Kaur & Anurag Kuhad. (2021) The Nrf2 pathway in psychiatric disorders: pathophysiological role and potential targeting. Expert Opinion on Therapeutic Targets 25:2, pages 115-139.
Read now
Read now
Articles from other publishers (21)
Riley Kessler, Sonal Sharma & David R Lynch. (2023) Omaveloxolone for the Treatment of Friedreich’s Ataxia. US Neurology 19:2, pages 2.
Crossref
Crossref
Dagmar Timmann & Winfried Ilg. 2023. Essentials of Cerebellum and Cerebellar Disorders. Essentials of Cerebellum and Cerebellar Disorders
699
703
.
Vadivelan Ramachandran, Tharani Mohanasundaram, Ruchi Tiwari, Gaurav Tiwari, Putta Vijayakumar, Bhargav Bhongiri & Rinu Mary Xavier. (2022) Nrf2 Mediated Heme Oxygenase-1 Activation Contributes to Diabetic
Wound Healing – an Overview. Drug Research 72:09, pages 487-495.
Crossref
Crossref
Adam J. Cohen‐Nowak, Alexa J. Cohen, Emily D. Correia, Carla P. Portocarrero, Andrew P. South & Neda Nikbakht. (2022) Omaveloxolone attenuates squamous cell carcinoma growth and disease severity in an Epidermolysis Bullosa mouse model. Experimental Dermatology 31:7, pages 1083-1088.
Crossref
Crossref
Adam J. Luginbuhl, Kealan HobelmannJulianna RodinSanket ShuklaUlrich RodeckAlban Linnenbach. (2021)
Synthetic Triterpenoid
RTA
‐408: Limits Radiation Damage to Normal Tissue
. The Laryngoscope 132:6, pages 1196-1204.
Crossref
Crossref
Andrey V. Markov, Anna A. Ilyina, Oksana V. Salomatina, Aleksandra V. Sen’kova, Alina A. Okhina, Artem D. Rogachev, Nariman F. Salakhutdinov & Marina A. Zenkova. (2022) Novel Soloxolone Amides as Potent Anti-Glioblastoma Candidates: Design, Synthesis, In Silico Analysis and Biological Activities In Vitro and In Vivo. Pharmaceuticals 15:5, pages 603.
Crossref
Crossref
Mihaela Stoia & Simona Oancea. (2022) Low-Molecular-Weight Synthetic Antioxidants: Classification, Pharmacological Profile, Effectiveness and Trends. Antioxidants 11:4, pages 638.
Crossref
Crossref
Libin Hu, Yang Cao, Huaijun Chen, Lei Xu, Qiguo Yang, Hang Zhou, Jianru Li, Qian Yu, Zhangqi Dou, Yin Li, Feng Yan, Fuyi Liu & Gao Chen. (2022) The Novel Nrf2 Activator Omaveloxolone Regulates Microglia Phenotype and Ameliorates Secondary Brain Injury after Intracerebral Hemorrhage in Mice. Oxidative Medicine and Cellular Longevity 2022, pages 1-18.
Crossref
Crossref
Maximillian Taro William Lee, William Mahy & Mark David Rackham. (2021) The medicinal chemistry of mitochondrial dysfunction: a critical overview of efforts to modulate mitochondrial health. RSC Medicinal Chemistry 12:8, pages 1281-1311.
Crossref
Crossref
Zhengqi Cheng, Yue Li, Xue Zhu, Ke Wang, Youmna Ali, Wenying Shu, Ting Zhang, Ling Zhu, Michael Murray & Fanfan Zhou. (2021) The Potential Application of Pentacyclic Triterpenoids in the Prevention and Treatment of Retinal Diseases. Planta Medica 87:07, pages 511-527.
Crossref
Crossref
David R Lynch & Joseph Johnson. (2021) Omaveloxolone: potential new agent for Friedreich ataxia. Neurodegenerative Disease Management 11:2, pages 91-98.
Crossref
Crossref
María Belen Cancela, Santiago Zugbi, Ursula Winter, Ana Laura Martinez, Claudia Sampor, Mariana Sgroi, Jasmine H. Francis, Ralph Garippa, David H. Abramson, Guillermo Chantada & Paula Schaiquevich. (2020) A decision process for drug discovery in retinoblastoma. Investigational New Drugs 39:2, pages 426-441.
Crossref
Crossref
Rory J. Tinker, Albert Z. Lim, Renae J. Stefanetti & Robert McFarland. (2021) Current and Emerging Clinical Treatment in Mitochondrial Disease. Molecular Diagnosis & Therapy 25:2, pages 181-206.
Crossref
Crossref
Paul S. Baxter, Nóra M. Márkus, Owen Dando, Xin He, Bashayer R. Al-Mubarak, Jing Qiu & Giles E. Hardingham. (2021) Targeted de-repression of neuronal Nrf2 inhibits α-synuclein accumulation. Cell Death & Disease 12:2.
Crossref
Crossref
Robert D.S. Pitceathly, Nandaki Keshavan, Joyeeta Rahman & Shamima Rahman. (2020) Moving towards clinical trials for mitochondrial diseases. Journal of Inherited Metabolic Disease 44:1, pages 22-41.
Crossref
Crossref
Riccardo Turchi, Raffaella Faraonio, Daniele Lettieri-Barbato & Katia Aquilano. (2020) An Overview of the Ferroptosis Hallmarks in Friedreich’s Ataxia. Biomolecules 10:11, pages 1489.
Crossref
Crossref
Scott A. Reisman, Deborah A. Ferguson, Chun‐Yue I. Lee & Joel W. Proksch. (2020) Omaveloxolone and TX63682 are hepatoprotective in the STAM mouse model of nonalcoholic steatohepatitis. Journal of Biochemical and Molecular Toxicology 34:9.
Crossref
Crossref
Laura R. Rodríguez, Tamara Lapeña, Pablo Calap-Quintana, María Dolores Moltó, Pilar Gonzalez-Cabo & Juan Antonio Navarro Langa. (2020) Antioxidant Therapies and Oxidative Stress in Friedreich’s Ataxia: The Right Path or Just a Diversion?. Antioxidants 9:8, pages 664.
Crossref
Crossref
Sharadha Dayalan Naidu & Albena T. Dinkova-Kostova. (2020) KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease. Open Biology 10:6.
Crossref
Crossref
Luiz H.M. Bozi, Juliane C. Campos, Vanessa O. Zambelli, Nikolas D. Ferreira & Julio C.B. Ferreira. (2020) Mitochondrially-targeted treatment strategies. Molecular Aspects of Medicine 71, pages 100836.
Crossref
Crossref
Monica M. Kangussu-Marcolino, Gretchen M. Ehrenkaufer, Emily Chen, Anjan Debnath & Upinder Singh. (2019) Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia. International Journal for Parasitology: Drugs and Drug Resistance 11, pages 80-94.
Crossref
Crossref